Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
WALTHAM, Mass., Oct. 13, 2016 -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, will ring the Closing Bell at Nasdaq today in celebration of its recently closed $30 million financing. Histogenics President and CEO, Adam Gridley will be joined by the Company’s executive team and colleagues for the Closing Bell ceremony beginning at 3:45 pm ET.
A livestream of the Nasdaq Closing Bell will be available from 3:45 to 4:00 p.m. EDT at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx.
About Histogenics Corporation
Histogenics is a leading regenerative medicine company developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions to treat musculoskeletal-related conditions. Histogenics’ first investigational product candidate, NeoCart®, is currently in Phase 3 clinical development. NeoCart is an autologous cell therapy designed to treat cartilage defects in the knee using the patient’s own cells. Knee cartilage defects represent a significant opportunity in the United States, with an estimated 500,000 or more applicable procedures each year. NeoCart is designed to exhibit characteristics of articular, hyaline cartilage prior to and upon implantation into the knee and therefore does not rely on the body to make new cartilage, characteristics not exhibited in other current treatment options. For more information, please visit www.histogenics.com.
Contact: Investor Relations Tel: +1 (781) 547-7909 [email protected]
